Drug-Drug Interaction between Psychiatric Medications and Experimental Treatments for Coronavirus Disease-19: A Mini-Review

Hananeh Baradaran; Nazanin Gorgzadeh; Houman Seraj; Anahita Asadi; Danial Shamshirian; Maryam Rezapour

doi:10.3889/oamjms.2020.5010

Authors

Hananeh Baradaran Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
Nazanin Gorgzadeh Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
Houman Seraj Student Research Committee, School of Pharmacy, Mazandaran University of Medical Science, Sari, Iran
Anahita Asadi Student Research Committee, School of Pharmacy, Mazandaran University of Medical Science, Sari, Iran
Danial Shamshirian Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Maryam Rezapour Department of Psychiatry, Psychiatry and Behavioral Research Center, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

DOI:

https://doi.org/10.3889/oamjms.2020.5010

Keywords:

COVID-19, Drug-drug interaction, Mental disorders, Psychopathy, Pharmacotherapy, Psychiatry, SARS-CoV-2, Psychopharmacology

Abstract

The pandemic of coronavirus disease (COVID)-2019 has been affected many people all around the world. Patients with mental disorders are not as safe as others; also, they might be more vulnerable in such situations. These patients take various medications, which can lead to numerous drug-drug interactions with experimental drugs uses against COVID-19. According to the potential critical interactions, we reviewed the reputable databases to find the interactions between main categories of psychiatric medications (e.g., antidepressants, anti-psychotics, sedative/hypnotics, and mood stabilizers) when used in concomitant with COVID-19 experimental agents (e.g., hydroxychloroquine, lopinavir/ritonavir, atazanavir, and chloroquine). We hope the list provided in this review helps the clinical care staff in treating patients with mental illness infected with severe acute respiratory syndrome coronavirus 2 during the COVID-19 pandemic.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of Coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-20.

World Health Organization. Coronavirus Disease 2019 (COVID-19): Situation Report No. 72. Geneva: World Health Organization; 2020.

Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC, et al. Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis. 2020:ciaa478. PMid:32338708

Beck BR, Shin B, Choi Y, Park S, Kang K. Predicting commercially available antiviral drugs that may act on the novel Coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model. Comput Struct Biotechnol J. 2020;18:784-90. https://doi. org/10.1101/2020.01.31.929547 PMid:32280433

Contini A. Virtual Screening of an FDA Approved Drugs Database on Two COVID-19 Coronavirus Proteins; 2020. https://doi.org/10.26434/chemrxiv.11847381.v1

Charlson F, van Ommeren M, Flaxman A, Cornett J, Whiteford H, Saxena S. New WHO prevalence estimates of mental disorders in conflict settings: A systematic review and meta-analysis. Lancet. 2019;394(10194):240-8. https://doi.org/10.1016/ s0140-6736(19)30934-1 PMid:31200992

Seminog OO, Goldacre MJ. Risk of pneumonia and pneumococcal disease in people with severe mental illness: English record linkage studies. Thorax. 2013;68(2):171-6. https://doi.org/10.1136/thoraxjnl-2012-202480 PMid:23242947

China Newsweek Collective Infections of Coronavirus among 50 Patients and 30 Health Workers in One Psychiatric Hospital in Wuhan, Shanghai Obs.; 2020.

Yao H, Chen JH, Xu YF. Patients with mental health disorders in the COVID-19 epidemic. Lancet Psychiatry. 2020;7(4):e21. https://doi.org/10.1016/s2215-0366(20)30090-0 PMid:32199510

Sartorious N. Comorbidity of mental and physical diseases: A main challenge for medicine of the 21st century. Shanghai Arch Psychiatry. 2013;25(2):68. PMid:24991137

Foisy MM, Yakiwchuk EM, Hughes CA. Induction effects of ritonavir: Implications for drug interactions. Ann Pharmacother. 2008;42(7-8):1048-59. https://doi.org/10.1345/aph.1k615 PMid:18577765

Wood R. Atazanavir: Its role in HIV treatment. Expert Rev Anti Infect Ther. 2008;6(6):785-96. PMid:19053892

Barnes K. Evidence Review Group Meeting on Cardiotoxicity of Antimalarials. United States: Stanford University; 2016.

Lexi-Interact™. Lexicomp Wolters Kluwer Health, Inc.; 2020. Available from: https://store.wolterskluwercdi.com/CDI. [Last accessed on 2020 Jan 15].

Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for Coronavirus disease 2019 (COVID-19): A review. JAMA. 2020;323(18):1824-36. https:// doi.org/10.1001/jama.2020.6019 PMid:32282022

Up To Date®, Wolters Kluwer Health; 2020. Available from: https:// www.uptodate.com/home. [Last accessed on 2020 Jan 15].

Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: What to expect for COVID-19? Int J Antimicrob Agents. 2020;55(5):105938. https://doi.org/10.1016/j.ijantimicag.2020.105938 PMid:32171740

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of Antiretroviral Agents in Adults and Adolescents Living with HIV. [Last accessed on 2020 Jan 15].

LDI Group. Interactions with Experimental COVID-19 Therapies; 2020. Available from: http://www.covid19-druginteractions.org. [Last accessed on 2020 Jan 15].

Ouellet D, Hsu A, Qian J, Lamm JE, Cavanaugh JH, Leonard JM, et al. Effect of fluoxetine on pharmacokinetics of ritonavir. Antimicrob Agents Chemother. 1998;42(12):3107-12. https://doi.org/10.1128/aac.42.12.3107 PMid:9835499

DeSilva KE, Le Flore DB, Marston BJ, Rimland D. Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine. AIDS. 2001;15(10):1281-5. https://doi. org/10.1097/00002030-200107060-00010 PMid:11426073

Preston CL. Stockley’s Drug interactions Pocket Companion. 2nd ed. London: Pharmaceutical Press; 2015.

Goodlet KJ, Zmarlicka MT, Peckham AM. Drug-drug interactions and clinical considerations with co-administration of antiretrovirals and psychotropic drugs. CNS Spectr. 2019;24(3):287-312. https://doi.org/10.1017/s109285291800113x PMid:30295215

Freerksen S, Saitz M, Osawa G. HAART and psychotropic drug interactions toolbox. Ment Health Clin. 2013;2(9):254-73. https://doi.org/10.9740/mhc.n140751

Hogeland G, Swindells S, McNabb J, Kashuba A, Yee GC, Lindley C. Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects. Clin Pharmacol Ther. 2007;81(1):69-75. https://doi.org/10.1038/sj.clpt.6100027 PMid:17186001

Hesse LM, von Moltke LL, Shader RI, Greenblatt DJ. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: Potential drug interactions with bupropion. Drug Metab Dispos. 2001;29(2):100-2. PMid:11159797

Penzak SR, Hon YY, Lawhorn WD, Shirley KL, Spratlin V, Jann MW. Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. J Clin Psychopharmacol. 2002;22(4):366-70. https://doi.org/10.1097/00004714-200208000-00006 PMid:12172335

Greenblatt DJ, von Moltke LL, Harmatz JS, Durol AL, Daily JP, Graf JA, et al. Alprazolam-ritonavir interaction: Implications for product labeling. Clin Pharmacol Ther. 2000;67(4):335-41. https://doi.org/10.1067/mcp.2000.105757 PMid:10801241

Greenblatt DJ, Harmatz J, Durol A, Daily J, Graf J, Mertzanis P, et al. Differential impairment of triazolam and zolpidem clearance by ritonavir. J Acquir Immune Defic Syndr. 2000;24(2):129-36. https://doi.org/10.1097/00126334-200006010-00007 PMid:10935688

Antonio JM, Grau S, Gimeno-Bayón JL, Carmona A. Ritonavir-induced carbamazepine toxicity. Ann Pharmacother. 2001;35(1):125-6. https://doi.org/10.1345/aph.10039 PMid:11197575

Burman W, Orr L. Carbamazepine toxicity after starting combination antiretroviral therapy including ritonavir and efavirenz. AIDS. 2000;14(17):2793-4. https://doi. org/10.1097/00002030-200012010-00022 PMid:11125901

Sheehan NL, Brouillette MJ, Delisle MS, Allan J. Possible interaction between lopinavir/ritonavir and valproic acid exacerbates bipolar disorder. Ann Pharmacother. 2006;40(1):147-50. https://doi.org/10.1345/aph.1g418 PMid:16368918

DiCenzo R, Peterson D, Cruttenden K, Morse G, Riggs G, Gelbard H, et al. Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virusinfected adults. Antimicrob Agents Chemother. 2004;48(11):4328- 31. https://doi.org/10.1128/aac.48.11.4328-4331.2004 PMid:15504860

van der Lee MJ, Dawood L, ter Hofstede HJ, de Graaff-Teulen MJ, van Ewijk-Beneken Kolmer EW, Caliskan-Yassen N, et al. Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. Clin Pharmacol Ther. 2006;80(2):159-68. https://doi.org/10.1016/j.clpt.2006.04.014 PMid:16890577

Burger D, Huisman A, van Ewijk N, Neisingh H, Rongen G, Koopmans P, et al., editors. The effect of atazanavir and atazanavir/ritonavir on UGT1A4 using lamotrigine as a phenotypic probe. In: 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles; 2007. https://doi. org/10.1038/clpt.2008.106

Gregoire M, Le Turnier P, Gaborit BJ, Veyrac G, Lecomte R, Boutoille D, et al. Lopinavir pharmacokinetics in COVID-19 patients. J Antimicrob Chemother. 2020;75(9):2702-4. https:// doi.org/10.1093/jac/dkaa195 PMid:32443151

Larrouquere L, Gabin M, Poingt E, Mouffak A, Hlavaty A, Lepelley M, et al. Genesis of an emergency public drug information website by the French society of pharmacology and therapeutics during the COVID-19 pandemic. Fundam Clin Pharmacol. 2020;34(3):389-96. https://doi.org/10.1111/fcp.12564 PMid:32394481

Lê MP, Peiffer-Smadja N, Guedj J, Néant N, Mentré F, Ader F, et al. Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial. J Antimicrob Chemother. 2020;75(9):2376-80. https://doi. org/10.1093/jac/dkaa191 PMid:32473020

English BA, Dortch M, Ereshefsky L, Jhee S. Clinically significant psychotropic drug-drug interactions in the primary care setting. Curr Psychiatry Rep. 2012;14(4):376-90. https:// doi.org/10.1007/s11920-012-0284-9 PMid:22707017

Morgan ET. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther. 2009;85(4):434-8. https://doi.org/10.1038/clpt.2008.302 PMid:19212314

Ofotokun I, Lennox JL, Eaton ME, Ritchie JC, Easley KA, Masalovich SE, et al. Immune activation mediated change in alpha-1-acid glycoprotein: Impact on total and free lopinavir plasma exposure. J Clin Pharmacol. 2011;51(11):1539-48. https://doi.org/10.1177/0091270010385118 PMid:21209245

Zarghami M. Psychiatric aspects of Coronavirus (2019-nCoV) infection. Iran J Psychiatry Behav Sci. 2020;14(1):e102957. https://doi.org/10.5812/ijpbs.102957